NCT00180011View on ClinicalTrials.gov

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Asthma
Interventions
DRUG

Omalizumab

injectable medication

Trial Locations (1)

10032

Columbia University, New York

Sponsors

Collaborators (2)

Genentech, Inc.
Novartis
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

DiMango, Emily, M.D.

INDIV